DK1443967T3 - Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor - Google Patents

Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor

Info

Publication number
DK1443967T3
DK1443967T3 DK02787572T DK02787572T DK1443967T3 DK 1443967 T3 DK1443967 T3 DK 1443967T3 DK 02787572 T DK02787572 T DK 02787572T DK 02787572 T DK02787572 T DK 02787572T DK 1443967 T3 DK1443967 T3 DK 1443967T3
Authority
DK
Denmark
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
DK02787572T
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1443967T3 publication Critical patent/DK1443967T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02787572T 2001-11-06 2002-11-05 Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor DK1443967T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17
PCT/EP2002/012343 WO2003039599A1 (en) 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Publications (1)

Publication Number Publication Date
DK1443967T3 true DK1443967T3 (da) 2007-04-16

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787572T DK1443967T3 (da) 2001-11-06 2002-11-05 Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor

Country Status (22)

Country Link
US (3) US7402603B2 (da)
EP (1) EP1443967B1 (da)
JP (1) JP4413614B2 (da)
KR (1) KR100937064B1 (da)
CN (1) CN100457183C (da)
AT (1) ATE352319T1 (da)
AU (1) AU2002351844B2 (da)
BR (1) BR0213932A (da)
CA (1) CA2461373A1 (da)
CY (1) CY1106508T1 (da)
DE (1) DE60217895T2 (da)
DK (1) DK1443967T3 (da)
ES (1) ES2280597T3 (da)
HU (1) HUP0402370A3 (da)
IL (2) IL160970A0 (da)
MX (1) MXPA04004312A (da)
NO (1) NO20042148L (da)
NZ (1) NZ544689A (da)
PL (1) PL205853B1 (da)
PT (1) PT1443967E (da)
RU (1) RU2311200C2 (da)
WO (1) WO2003039599A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1780210A4 (en) * 2004-08-11 2009-06-10 Kyorin Seiyaku Kk NEW CYCLIC AMINOBENOIC ACID DERIVATIVE
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN102584673B (zh) * 2006-06-12 2014-08-06 诺华股份有限公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物
EP2394991B1 (en) 2006-06-12 2015-09-23 Novartis AG Process for making starting materials for N-hydroxy-3-[4-[2-(2-methyl-1 H-indol-3-yl)-ethylaminomethyl]-phenyl]-2E-2-propenamide
BRPI0713653A2 (pt) * 2006-06-12 2012-10-23 Novartis Ag processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
WO2008002634A1 (en) * 2006-06-28 2008-01-03 Novartis Ag Use of hdac inhibitors for the treatment of lymphomas
EP2055692A4 (en) * 2006-08-25 2010-07-07 Asahi Glass Co Ltd PROCESS FOR PRODUCING 1,2-DIALCOXY-3-FLUOROBENZENE
AU2008214299B2 (en) 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
EA018618B1 (ru) 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
RU2640416C2 (ru) * 2012-04-16 2018-01-09 Тоа Эйо Лтд. Бициклическое соединение
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
PL205853B1 (pl) 2010-06-30
NZ544689A (en) 2007-08-31
RU2004117170A (ru) 2005-04-20
AU2002351844B2 (en) 2006-12-21
IL160970A (en) 2010-06-30
DE60217895D1 (en) 2007-03-15
BR0213932A (pt) 2004-08-31
US20080227845A1 (en) 2008-09-18
JP4413614B2 (ja) 2010-02-10
IL160970A0 (en) 2004-08-31
EP1443967A1 (en) 2004-08-11
PL368539A1 (en) 2005-04-04
HUP0402370A2 (hu) 2005-02-28
PT1443967E (pt) 2007-04-30
US20090192211A1 (en) 2009-07-30
JP2005510517A (ja) 2005-04-21
RU2311200C2 (ru) 2007-11-27
NO20042148L (no) 2004-08-04
DE60217895T2 (de) 2007-07-05
ATE352319T1 (de) 2007-02-15
WO2003039599A1 (en) 2003-05-15
KR100937064B1 (ko) 2010-01-15
KR20050043744A (ko) 2005-05-11
US20050032899A1 (en) 2005-02-10
EP1443967B1 (en) 2007-01-24
US7402603B2 (en) 2008-07-22
CN1578674A (zh) 2005-02-09
CY1106508T1 (el) 2012-01-25
CN100457183C (zh) 2009-02-04
ES2280597T3 (es) 2007-09-16
CA2461373A1 (en) 2003-05-15
MXPA04004312A (es) 2005-05-16
HUP0402370A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
DK1443967T3 (da) Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BR9914044A (pt) ésteres tetrahidropirido
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
ATE408601T1 (de) Fredericamycin-derivate
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ATE438618T1 (de) Inhibitoren von humanem adam-10
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HK1087010A1 (en) Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
PL370361A1 (en) Alkyl urea retinoid agonists i
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
DE602004008247D1 (de) Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält
BR0212607A (pt) Agonistas retinóides ii de uréia substituìda
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona